Sommaire de 12 mois d'activités de lobbying - Lobbyistes salariés d'entreprises

Objets

• Affaires autochtones
• Budget
• Commerce international
• Commerce intérieur
• Développement régional
• Environnement
• Impôts et finances
• Industrie
• Marchés publics
• Propriété intellectuelle
• Questions touchant les consommateurs
• Recherche et développement
• Santé
• Sciences et technologies
• Travail

Détails sur l'objet

Politique ou Programme

• Canadian Institutes of Health (CIHR) initiatives, such as the Drug Safety and Effectiveness Network (DSEN), and various research programs, particularly as they relate to public/private research and development partnerships
• Development of a Canadian National Pharmacare Program with a primary focus on improving patient well-being and health outcomes access to effective treatments for patients.
• Environment and Climate Change Canada and/or Food and Drugs Act regulations as they relate to the safe and environmentally responsible disposal of biopharmaceutical compounds.
• Existing or proposed policies and programs related to improving access to effective treatments for common mental health, addiction and neuro-degenerative for Canadian patients.
• Federal Health Partnership with respect to the co-ordination of federal health benefit plan policies and programs.
• Federal policies related to, and interactions with, the Canadian Agency for Drugs and Technologies in Health (CADTH) particularly pertaining to its Common Drug Review (CDR), Health Technology Assessment (HTA), and the Canadian Optimal Medication Prescribing & Utilization Service (COMPUS) units.
• Health Canada (including the Office of Patented Medicines and Liason (OPML)) policies and regulations with regards to therapeutic products
• Health benefits programs of Immigration, Refugees and Citizenship Canada, Correctional Services of Canada, Health Canada (NIHB), the Department of National Defence, the Royal Canadian Mounted Police, and Veterans Affairs Canada with respect to decisions and policies which impact the reimbursement of biopharmaceutical therapeutic products for plan beneficiaries.
• International Trade Canada's "Invest in Canada" policies and programs with respect to investment, business development and innovation in the life sciences industry sector.
• Mobilizing Science and Technology to Canada's Advantage, the federal science and technology strategy, with respect to the health and related life sciences and technologies priority area
• Modernization of Health Canada's Progressive Licensing framework as it relates to the review and approval of biopharmaceutical products
• National Pharmaceutical Strategy (NPS) as it relates to the federal government's involvement in the federal/provincial/territorial governments' access to medicines framework
• Pan-Canadian Pricing Alliance as it relates to drug pricing and reimbursement.
• Scientific Research and Experimental Development (SR&ED) Tax Incentive Program as it relates to investment in biopharmaceutical and related health technology innovation.

Politique ou Programme, Proposition législative, Projet de loi ou résolution

• International Trade policy initiatives related to implementing / strengthening the Canada-Europe Trade Agreement (CETA)and the Trans-Pacific Partnership (TPP), including recognition of patent term restoration within Canada's intellectual property protection regime

Politique ou Programme, Règlement

• Data exclusivity as it relates to the use of Natural Health Products in biopharmaceutical preparations.
• Patent Act as it relates to the regulation of intellectual property for therapeutic products

Proposition législative, Projet de loi ou résolution

• Food and Drugs Act, specifically with respect to the approval, regulation and life-cycle management of therapeutic products

Proposition législative, Projet de loi ou résolution, Règlement

• Food and Drugs Act & regulations as they relate to export restrictions and cross border trade of biopharmaceuticals.

Règlement

• Food and Drug Regulations as it relates to data protection (Section C.08.004) and the regulation and protection of biopharmaceutical products
• Patent Act with respect to Patented Medecines (Notice of Compliance (NOC)) Regulations and to Patented Medicines Regulations.
• Patented Medicines Prices Review Board (PMPRB) Regulations as they relate to reporting requirements and pricing guidelines as well as reference pricing and the modernization of PMPRB regulatory framework.